Literature DB >> 2448128

Ketoconazole inhibits corticotropic cell function in vitro.

G K Stalla1, J Stalla, M Huber, J P Loeffler, V Höllt, K von Werder, O A Müller.   

Abstract

The effects of ketoconazole (KC) on secretion and biosynthesis of ACTH and generation of cAMP in rat anterior pituitary cells were investigated in vitro. KC inhibits CRF-stimulated ACTH release from rat anterior pituitary fragments in a dose-dependent fashion between 1.5 and 100 microM. The effect of CRF as a releaser of ACTH was fully restored after KC was removed from the medium. Similar effects were observed in primary cultures of rat anterior pituitary cells. KC dose-dependently decreased basal and CRF-stimulated ACTH release. In addition, basal and CRF-stimulated mRNA coding for the ACTH precursor were reduced after preincubation with KC. The effects of KC on ACTH release and biosynthesis seem to be mediated by cAMP, since KC inhibits basal and CRF-stimulated cAMP release and content within the same dose range. Since the stimulatory effects of cholera toxin, sodium fluoride, and forskolin were dose-dependently inhibited by KC and since the addition of (Bu)2cAMP abolished the inhibiting effect of KC, it is concluded that KC acts by inhibition of the catalytic component of the adenylate cyclase holoenzyme.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2448128     DOI: 10.1210/endo-122-2-618

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  18 in total

1.  Iatrogenic heart block during treatment of a patient with Cushing's syndrome: report of a case.

Authors:  J P Brito; E Singh; A Basu
Journal:  Endocrine       Date:  2012-04       Impact factor: 3.633

Review 2.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 3.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 4.  Medical therapy of Cushing's disease.

Authors:  Lynnette K Nieman
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

5.  Current trends in the endocrine use of ketoconazole.

Authors:  N Sonino
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

6.  Characterization of Interleukin-2 (IL-2) receptor expression and action of IL-2 and IL-6 on normal anterior pituitary cell growth.

Authors:  E Arzt; J Sauer; R Buric; J Stalla; U Renner; G K Stalla
Journal:  Endocrine       Date:  1995-02       Impact factor: 3.633

7.  Direct stimulation of adenylyl cyclase 9 by the fungicide imidazole miconazole.

Authors:  James Simpson; Adrienn Pálvölgyi; Ferenc A Antoni
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-01-03       Impact factor: 3.000

8.  Interleukin-2 and interleukin-2 receptor expression in human corticotrophic adenoma and murine pituitary cell cultures.

Authors:  E Arzt; G Stelzer; U Renner; M Lange; O A Müller; G K Stalla
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 9.  Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas.

Authors:  Marta Labeur; Marcelo Paez-Pereda; Eduardo Arzt; Günter K Stalla
Journal:  Rev Endocr Metab Disord       Date:  2008-07-07       Impact factor: 6.514

Review 10.  Recent developments in drug therapy for Cushing's disease.

Authors:  Rob van der Pas; Wouter W de Herder; Leo J Hofland; Richard A Feelders
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.